CNCR - Loncar Cancer Immunotherapy ETF
|Ex-Dividend Date||Dec 30, 2020|
|Trading Day||April 21|
|Day's Range||28.85 - 29.79|
|52-Week Range||21.54 - 35.82|
The investment seeks to track the total return performance, before fees and expenses, of the Loncar Cancer Immunotherapy Index. The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the fund's index provider, as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. Normally it will invest at least 80% of its total assets in the component securities of the index. The fund is non-diversified.
|Asset Class |
|Inception Date |
Oct 13, 2015
|Ticker Symbol |
|Index Tracked |
Loncar Cancer Immunotherapy Index
Top 10 Holdings45.42% of assets
|Dec 30, 2020||$0.288||Jan 4, 2021|
|Dec 28, 2017||$0.3502||Jan 2, 2018|
|Dec 29, 2015||$0.106||Jan 4, 2016|
Both stock index ETFs and biotech stocks and ETFs have been on a tear lately thanks to promising coronavirus vaccine developments from several major pharmaceutical companies. But this week, the U.K. bec...
Healthcare stocks and ETFs are continuing to outperform as investors are optimistic about an upcoming vaccine for the coronavirus, which has been a blight on the globe since early this year. There has b...
We have highlighted ETFs that were at the forefront of the market rebound on Sep 9 and will continue to do so if market sentiments remain positive.
Stock futures rocketed higher and are continuing the uptrend in overnight trading on Tuesday after Moderna said its coronavirus vaccine generated antibodies in all patients in an early trial, creating o...
With the race to find a vaccine for the coronavirus, now drugmaker AstraZeneca is the latest to receive funding to generate a panacea.
U.S. stocks are continuing to soar higher on Monday, moving into positive territory for May, following news that drugmaker Moderna released positive, preliminary results from the first human trial of it...
The rising incidence of cancer cases has encouraged several major pharmaceutical and biotech players to invest substantially in the developments of drugs.
Biotechnology company Amgen (NasdaqGS: AMGN) is throwing $2.7 billion into BeiGene (NasdaqGS: BGNE), sending the Chinese biotech’s shares surging and bolstering sector-related ETFs. Among the top perfor...